These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2403488)

  • 1. Accelerated genetic destabilization and dormancy: two distinct causes of resistance in metastatic cells; clinical magnitude, therapeutic approaches.
    Israel L
    Clin Exp Metastasis; 1990; 8(1):1-11. PubMed ID: 2403488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seeing the invisible: how mathematical models uncover tumor dormancy, reconstruct the natural history of cancer, and assess the effects of treatment.
    Hanin L
    Adv Exp Med Biol; 2013; 734():261-82. PubMed ID: 23143983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A model for metastases formation.
    Markovitch S
    Int J Biomed Comput; 1993 Jan; 32(1):19-33. PubMed ID: 8425750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of multicellular resistance on the survival of solid tumors, including micrometastases.
    Kerbel RS
    Invasion Metastasis; 1994-1995; 14(1-6):50-60. PubMed ID: 7657532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases.
    Naumov GN; Townson JL; MacDonald IC; Wilson SM; Bramwell VH; Groom AC; Chambers AF
    Breast Cancer Res Treat; 2003 Dec; 82(3):199-206. PubMed ID: 14703067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of retinoic acid on the growth of isogenic metastatic and non-metastatic breast cancer cell lines and their association with distinct expression of retinoic acid receptor beta isoforms 2 and 4.
    Hayashi K; Goodison S; Urquidi V; Tarin D; Lotan R; Tahara E
    Int J Oncol; 2003 Mar; 22(3):623-9. PubMed ID: 12579317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Cancer Cell Dormancy.
    Recasens A; Munoz L
    Trends Pharmacol Sci; 2019 Feb; 40(2):128-141. PubMed ID: 30612715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling growth kinetics and statistical distribution of oligometastases.
    Withers HR; Lee SP
    Semin Radiat Oncol; 2006 Apr; 16(2):111-9. PubMed ID: 16564446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor heterogeneity and drug resistance.
    Dexter DL; Leith JT
    J Clin Oncol; 1986 Feb; 4(2):244-57. PubMed ID: 3944607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genes and regulatory pathways involved in persistence of dormant micro-tumors.
    Almog N
    Adv Exp Med Biol; 2013; 734():3-17. PubMed ID: 23143972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastases in immune-mediated dormancy: a new opportunity for targeting cancer.
    Romero I; Garrido F; Garcia-Lora AM
    Cancer Res; 2014 Dec; 74(23):6750-7. PubMed ID: 25411345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of metastasis suppressor genes in metastatic dormancy.
    Horak CE; Lee JH; Marshall JC; Shreeve SM; Steeg PS
    APMIS; 2008; 116(7-8):586-601. PubMed ID: 18834404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonal dominance of primary tumours by metastatic cells: genetic analysis and biological implications.
    Kerbel RS; Waghorne C; Korczak B; Lagarde A; Breitman ML
    Cancer Surv; 1988; 7(4):597-629. PubMed ID: 3072068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis.
    Langley RR; Fidler IJ
    Endocr Rev; 2007 May; 28(3):297-321. PubMed ID: 17409287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanisms of metastasis].
    Burger MM
    Ther Umsch; 2001 Dec; 58(12):695-700. PubMed ID: 11797530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Uveal Melanoma Metastatic Rate With Stochastic Mutation Rate and Type of Mutation.
    Szalai E; Jiang Y; van Poppelen NM; Jager MJ; de Klein A; Kilic E; Grossniklaus HE
    JAMA Ophthalmol; 2018 Oct; 136(10):1115-1120. PubMed ID: 30073324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor dormancy: long-term survival in a hostile environment.
    Quesnel B
    Adv Exp Med Biol; 2013; 734():181-200. PubMed ID: 23143980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.